ornidazole has been researched along with Adverse Drug Event in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Cao, C; Luo, A; Wang, S; Weng, D; Wu, P; Zheng, H | 1 |
1 trial(s) available for ornidazole and Adverse Drug Event
| Article | Year |
|---|---|
Efficacy and safety of morinidazole in pelvic inflammatory disease: results of a multicenter, double-blind, randomized trial.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Anti-Infective Agents; China; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Middle Aged; Nitroimidazoles; Ornidazole; Pelvic Inflammatory Disease; Treatment Outcome; Virus Diseases; Young Adult | 2017 |
1 other study(ies) available for ornidazole and Adverse Drug Event
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |